ACTINOGEN MEDICAL LIMITED (ASX: ACW)
Health care · News and insights
Price unavailable
Latest ACW announcements
Announcement Insights
Actinogen Delays XanaMIA Results as It Analyses Additional Trial Data
Actinogen Medical’s expected mid-November topline results from its XanaMIA Alzheimer’s trial remain pending as the company analyses additional data, with its shares moving from a trading halt on November 13 to a voluntary suspension on November 17. The trial had reached database lock by October, but the company said further analysis was needed before releasing results.
Updated 17 Nov 2026, 10:43 AM Sydney time
Sources
Suspension from QuotationTrading HaltRequest for Trading HaltUpdate - Notification of buy-back - ACWNotification of cessation of securities - ACWResponse to ASX Price QueryLetter to Shareholders, Notice of AGM & Proxy FormComments
2026-11-17 · Health care
Actinogen Medical has requested a voluntary suspension while it completes further analysis of additional data received for its XanaMIA phase 2b/3 Alzheimer’s trial, ahead of releasing topline results. The suspension is requested to remain in place until the results announcement or the start of trading on Thursday.
Updated 2026-11-17 10:35
Sources
Suspension from QuotationComments
2026-11-13 · Health care
ACW: $0.045 +0.00% · MC: $182M
Actinogen Medical’s shares have been placed in a trading halt while the company reviews and analyses results from its XanaMIA Phase 2b/3 Alzheimer’s trial. The halt is expected to last until a material announcement or no later than Tuesday, 17 November.
Updated 2026-11-13 09:29
Sources
Request for Trading HaltTrading HaltComments
2026-11-12 · Health care
ACW: $0.045 -4.26% · MC: $182M
Actinogen Medical completed a nil-consideration employee share scheme buy-back, cancelling 4.4 million ordinary shares. The cancellation reduced ordinary shares on issue from about 3.87 billion to about 3.87 billion.
Updated 2026-11-12 16:33
Sources
Notification of cessation of securities - ACWUpdate - Notification of buy-back - ACWComments
2026-11-09 · Health care
ACW: $0.048 +17.07% · MC: $182M
Actinogen Medical told the ASX it knows of no unannounced information that could explain recent trading in its shares. It pointed to its October update that the XanaMIA Alzheimer’s trial had reached database lock, with topline results expected in mid-November 2026.
Updated 2026-11-09 16:37
Sources
Response to ASX Price QueryComments
2026-10-28 · Health care
ACW: $0.040 -2.44% · MC: $182M
Actinogen Medical will hold its 2026 annual general meeting on 30 November in Sydney and online. Shareholders can attend, ask questions and vote in person or through the online platform.
Updated 2026-10-28 11:01
Sources
Letter to Shareholders, Notice of AGM & Proxy FormComments
Comments